Salix announced that the FDA has granted priority review designation of its New Drug Application (NDA) for crofelemer 125mg tablets for the control and symptomatic relief of diarrhea in patients with human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS) on anti-retroviral therapy (ART).

Crofelemer is a locally acting, minimally absorbed product that is believed to possess dual novel mechanisms of action that may be effective in treating both acute infectious diarrhea and chronic diarrhea.

For more information, call (919) 862-1000 or visit